Novavax, Inc. (NVAX) Release: One Year Follow-Up From RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels Of Immune Response
5/12/2014 9:09:10 AM
GAITHERSBURG, Md., May 12, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) F-protein vaccine in 220 elderly adults (60 years of age and older, with a mean age of 68) that was initiated in October 2012. In the placebo-controlled trial, subjects received a single injection of either 60µg or 90µg of the RSV F-protein vaccine candidate, with or without aluminum phosphate as an adjuvant. - See more at: http://www.globenewswire.com/news-release/2014/05/12/635417/10081227/en/One-Year-Follow-Up-From-RSV-F-Protein-Vaccine-Candidate-Phase-1-Elderly-Trial-Demonstrates-Sustained-Levels-of-Immune-Response.html#sthash.BKdERmCs.dpuf
Help employers find you! Check out all the jobs and post your resume.
comments powered by